Thu, Mar 27, 8:21 PM (30 days ago)
### Summary of Financial Performance **Revenue:** - **2024:** $18.5 million - **2023:** $15.2 million - **Growth:** 22% **Net Income:** - **2024:** -$4.3 million - **2023:** -$5.9 million - **Improvement:** $1.6 million **Operating Expenses:** - **2024:** $11.8 million - **2023:** $13.6 million - **Reduction:** $1.8 million **Gross Profit:** - **2024:** $7.6 million - **2023:** $6.0 million - **Growth:** 26.7% ### Strategic Overview **Mission:** Address cancer misdiagnoses through innovative diagnostic products and services. **Products:** - **HemeScreen:** Genetic diagnostic panels for blood cancer. - **IV-Cell:** Proprietary cell culture media for simultaneous culturing of hematopoietic cell lineages. **Market Position:** - **Domestic Market:** U.S. oncology market with a total available market exceeding $20 billion. - **Growth Rate:** Estimated compound annual growth rate exceeding 5%. ### Future Outlook **Growth Strategy:** - Expand diagnostic product market share. - Increase laboratory adoption of cost-effective technologies. - Enhance genetic diagnostic expertise and proprietary technology. **Risk Factors:** - **Financial:** Significant working capital deficit and substantial operating losses. - **Market:** Competition from large commercial companies and specialized firms. - **Regulatory:** Compliance with FDA, CLIA, and other regulatory requirements. - **Operational:** Dependence on key personnel and potential labor shortages. ### Financial Condition **Cash Flow:** - **2024:** $0.4 million positive cash flow from operations. - **2023:** -$3.6 million negative cash flow from operations. **Debt:** - **Long-Term Debt:** $0.4 million as of December 31, 2024. - **Financing:** $3.7 million available for future sales pursuant to AGP 2023 Sales Agreement. **Market Position Changes:** - **Stock Performance:** Limited public market and potential volatility. - **Listing Maintenance:** Risk of delisting if Nasdaq criteria are not met. ### Conclusion Precipio, Inc. (PRPO) shows a mixed financial performance with significant revenue growth but ongoing net losses. The company's strategic focus on innovative diagnostic products and services positions it well in the growing oncology market. However, it faces substantial financial and operational risks, including regulatory compliance and market competition. Investors should monitor the company's ability to manage these risks and achieve profitability in the future.